Interestingly, subanalysis of a trial featuring HER2-positive breast cancer patients revealed that metformin-treated DM participants had better prognoses compared to patients not treated with metformin, whereas the outcomes of patients with HR-negative cancers were not affected by DM status [16]. The gene discussed is ERBB2; the disease is breast carcinoma.